Literature DB >> 1703987

Antigen presentation and HLA-DR expression by FK-506-treated human monocytes.

J Woo1, D J Propper, A W Thomson.   

Abstract

The novel macrolide immunosuppressant FK-506 demonstrated superior potency to cyclosporin A (CsA) in the inhibition of purified protein derivative (PPD)-induced human T-cell proliferation. Pulsing of monocytes with PPD for 24 hr in the presence of FK-506 did not impair their capacity to subsequently induced the proliferation of purified autologous T cells. In contrast, FK-506 profoundly inhibited the proliferative response of T cells to antigen-pulsed monocytes. Recombinant IL-2, but not IL-1, partially restored the proliferative response to PPD in the presence of the drug. FK-506 had no effect on basal or rIFN-gamma-induced expression of HLA-DR on monocytic cell line cells. These findings provide the first evidence that FK-506 can profoundly inhibit soluble antigen-induced human T-cell proliferation at concentrations which do not significantly impair the accessory function of mononuclear phagocytes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1703987      PMCID: PMC1384877     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  20 in total

1.  FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro.

Authors:  T Kino; H Hatanaka; S Miyata; N Inamura; M Nishiyama; T Yajima; T Goto; M Okuhara; M Kohsaka; H Aoki
Journal:  J Antibiot (Tokyo)       Date:  1987-09       Impact factor: 2.649

2.  Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation.

Authors:  S Sawada; G Suzuki; Y Kawase; F Takaku
Journal:  J Immunol       Date:  1987-09-15       Impact factor: 5.422

3.  Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. I. Inhibition of expression of alloantigen-activated suppressor cells, as well as induction of alloreactivity.

Authors:  N Yoshimura; S Matsui; T Hamashima; T Oka
Journal:  Transplantation       Date:  1989-02       Impact factor: 4.939

4.  Activity of the mononuclear phagocyte system in cyclosporin A-treated mice.

Authors:  L C McIntosh; A W Thompson
Journal:  Transplantation       Date:  1980-11       Impact factor: 4.939

5.  Inhibition of human monocyte antigen presentation, but not HLA-DR expression, by cyclosporine.

Authors:  D S Snyder; C L Wright; C Ting
Journal:  Transplantation       Date:  1987-09       Impact factor: 4.939

6.  The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes.

Authors:  M J Tocci; D A Matkovich; K A Collier; P Kwok; F Dumont; S Lin; S Degudicibus; J J Siekierka; J Chin; N I Hutchinson
Journal:  J Immunol       Date:  1989-07-15       Impact factor: 5.422

7.  A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin.

Authors:  J J Siekierka; S H Hung; M Poe; C S Lin; N H Sigal
Journal:  Nature       Date:  1989-10-26       Impact factor: 49.962

8.  FK 506 for liver, kidney, and pancreas transplantation.

Authors:  T E Starzl; S Todo; J Fung; A J Demetris; R Venkataramman; A Jain
Journal:  Lancet       Date:  1989-10-28       Impact factor: 79.321

9.  Cyclophilin: a specific cytosolic binding protein for cyclosporin A.

Authors:  R E Handschumacher; M W Harding; J Rice; R J Drugge; D W Speicher
Journal:  Science       Date:  1984-11-02       Impact factor: 47.728

10.  Cyclosporine inhibits macrophage-mediated antigen presentation.

Authors:  D A Palay; C W Cluff; P A Wentworth; H K Ziegler
Journal:  J Immunol       Date:  1986-06-15       Impact factor: 5.422

View more
  4 in total

Review 1.  FK 506 and autoimmune disease: perspective and prospects.

Authors:  A W Thomson; T E Starzl
Journal:  Autoimmunity       Date:  1992       Impact factor: 2.815

Review 2.  Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation.

Authors:  D H Peters; A Fitton; G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

3.  T-helper 2 cells are essential for modulation of vascular repair by allogeneic endothelial cells.

Authors:  Heiko Methe; Mamoru Nanasato; Anna-Maria Spognardi; Adam Groothuis; Elazer R Edelman
Journal:  J Heart Lung Transplant       Date:  2009-12-24       Impact factor: 10.247

Review 4.  Effect of Calcineurin Inhibitors and Mammalian Target of Rapamycin Inhibitors on the Course of COVID-19 in Kidney Transplant Recipients.

Authors:  Nuri Baris Hasbal; Didem Turgut; Ebru Gok Oguz; Sena Ulu; Ozkan Gungor
Journal:  Ann Transplant       Date:  2021-03-12       Impact factor: 1.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.